Even without weight loss, Wegovy appears to protect the heart

Four-year data from the SELECT trial will significantly bolster Novo Nordisk’s (NOVO: N) bid to become the GLP-1 company of choice for payers and prescribers.

Adding to earlier data in the important co-morbidity of cardiovascular disease, the latest results,  published in Nature, show that the apparent protective effects of Wegovy (semaglutide) were achieved, regardless of whether patients lost weight.

The company has already shown that treatment with Wegovy led to a statistically-significant and superior reduction in major adverse cardiovascular events, a reduction of around a fifth compared to placebo.